.Attributes Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ innovative breast cancer as well as energetic or stable brain metastases presented constant intracranial activity and also systemic effectiveness of T-DXd.